A Proof of Concept (POC) Clinical Trial for Post-Traumatic Stress Disorder (PTSD) With a First-In-Class Vasopressin 1a Receptor Antagonist (SRX246)
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs SRX 246 (Primary)
- Indications Post-traumatic stress disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Azevan Pharmaceuticals
- 03 Feb 2017 Status changed from not yet recruiting to recruiting.
- 29 Sep 2016 Planned initiation date changed from 1 Jun 2016 to 1 Nov 2016.
- 13 Apr 2016 New trial record